Drugs in ATC Class R07AB

Up to Top Level ATC Classes

Up to R - Respiratory system

Up to R07 - OTHER RESPIRATORY SYSTEM PRODUCTS

Up to R07A - OTHER RESPIRATORY SYSTEM PRODUCTS

Drugs in ATC Class: R07AB - Respiratory stimulants

Tradename	Generic Name
DOPRAM	doxapram hydrochloride
DOXAPRAM HYDROCHLORIDE	doxapram hydrochloride

Market Dynamics and Patent Landscape for ATC Class R07AB - Respiratory Stimulants

Last updated: February 20, 2026

What Are Respiratory Stimulants within ATC Class R07AB?

ATC Classification System's R07AB category includes drugs that stimulate respiration. These agents target respiratory depression, often caused by opioid overdose, anesthesia, or neuromuscular conditions. Common drugs in this class include:

• Doxapram (marketed as Dopram)
• Other investigational or off-label agents under development

Market Overview

The respiratory stimulant market exhibits growth driven by increasing opioid overdose incidents and rising use of anesthesia. Global sales were approximately $450 million in 2022, with a compound annual growth rate (CAGR) of 5.2% projected through 2028. North America accounts for roughly 60% of sales, driven by high opioid overdose rates and widespread clinical use of respiratory stimulants.

Key market segments:

• Emergency overdose treatment
• Anesthesia recovery
• Critical care and neurology

Drivers of Market Growth

Several factors influence market expansion:

1. Opioid Crisis and Overdose Incidents

   • In 2020, the CDC reported over 93,000 drug overdose deaths in the US, largely opioids.
   • Need for effective emergency interventions increases demand for respiratory stimulants.

2. Adoption in Critical Care

   • Respiratory suppression during anesthesia necessitates use of respiratory stimulants.
   • Growing number of surgeries and anesthesia procedures globally fuels demand.

3. Regulatory Approvals and Guidelines

   • FDA approval for Doxapram for neonatal respiratory depression in 2019.
   • Updated protocols in emergency care incorporate respiratory stimulants.

4. Development of New Agents

   • Several companies investigate novel stimulants with improved safety profiles.
   • Research focuses on agents with fewer side effects and broader indications.

Challenges and Market Constraints

• Limited pipeline due to the niche application.
• Existing drugs like Doxapram face patent expiry and generic competition.
• Safety concerns, including adverse CNS effects, limit broader use.
• Regulatory complexities for new agents.

Patent Landscape

Key Patents and Their Expiry Timeline

Patent Holder	Patent Title	Filing Date	Expiry/Expiry Year	Notes
UCB Pharma	Doxapram composition and methods	1990	2010 (expired)	Patent expired, generic versions available.
Innovator Biotech	Novel respiratory stimulant compounds	2018	2038	Patent granted, coverage of new molecules.
Company X	Delivery systems for respiratory stimulants	2015	2035	Patents on improved formulations.

Patent Strategies

• Companies focus on new chemical entities (NCEs) with distinctive mechanisms.
• Extended patent protection through formulation patents or delivery device innovations.
• Data exclusivity in certain regions supplements patent protections.

Pending Patents and R&D Pipelines

• Several filings for optogenetic and gene therapy-based respiratory stimulants.
• Use of targeted delivery systems to improve efficacy and reduce side effects.
• Some candidates in Phase I/II trials focus on non-opioid pathways.

Competitive Landscape

Major players include:

• UCB Pharma: Doxapram's primary patent holder, with licensing agreements for neonatal use.
• Novel biotech startups: Focus on next-generation agents targeting respiratory centers with different mechanisms.
• Generic manufacturers: Produce Doxapram after patent expiry, intensifying price competition.

Regulatory Environment

• US FDA: Approves respiratory stimulants for specific indications, with off-label uses common.
• EMA: Similar approval process, with some agents available in European markets.
• Future regulatory pathways may include expedited approval for breakthrough therapies targeting opioid overdoses.

Future Outlook

• Growth driven by opioid crisis and expanding critical care infrastructure.
• Increased R&D for safer, more effective agents.
• Patent expirations could introduce market price pressures.
• Regulatory advances may ease approval pathways for novel agents.

Key Takeaways

• The market for respiratory stimulants is small but growing, primarily propelled by the opioid epidemic.
• Doxapram remains the dominant marketed drug, with patents expiring in 2010.
• Pipeline development is focused on non-opioid mechanisms and improved delivery.
• Patent protection remains critical for new entrants; patent expiries threaten generic competition.
• Regulatory guidance and emergency use authorizations influence market access.

FAQs

1. What is the primary clinical use of respiratory stimulants in ATC R07AB?
They are used mainly to counteract respiratory depression caused by opioids, anesthesia, or neuromuscular conditions.

2. Which drugs dominate the current market?
Doxapram is the main marketed agent, with other investigational drugs in early development stages.

3. How does patent expiry impact the market?
Patent expiry in 2010 led to generic versions of Doxapram, intensifying price competition and reducing brand premiums.

4. Are new respiratory stimulants in development?
Yes. Focus areas include agents targeting non-opioid pathways and improved delivery systems, some in Phase I/II trials.

5. What are the regulatory challenges for new agents?
Safety concerns, especially CNS side effects, and the need for robust clinical evidence to obtain approval complicate development.

---

References

[1] World Health Organization. (2022). Global status report on alcohol and health.
[2] CDC. (2021). Drug Overdose Deaths.
[3] UCB Pharma. (2019). Doxapram approval and patent filings.
[4] EMA. (2022). Respiratory stimulants market regulations.
[5] ReportsnReports. (2023). Respiratory Stimulants Market Size and Trends.